Five highlights of the pharmaceutical industry in 2017
Release time:
2020-08-14
2017 NPC and CPPCC Five Major Points in Pharmaceutical Industry
3# September 3 , 2017 NPC and CPPCC will be held in Beijing. The issues and decisions of the NPC and CPPCC will directly affect the overall trends and trends of the industry in the following year and have a profound impact on the future economy and major assets. The following is a summary of the highlights of 5 in the pharmaceutical industry during the 2017 NPC and CPPCC sessions.
1 , Supply-side Reform: Value Chain Distribution Faces Reconstruction
The so-called supply-side reform is to promote the development of economic industry by liberating productivity from the supply and production sides. As early as last year's Spring Festival, the State Council meeting focused on the pharmaceutical industry and proposed measures such as "aiming at the urgent needs of the masses, improving the safety evaluation and product traceability system, combining the" three medical "linkage reform, and building a pharmaceutical circulation network throughout the township", hoping to promote the innovation and upgrading of the pharmaceutical industry through supply-side reform. From
to this year, the health planning Commission held a press conference on 2 8 , saying that through the implementation of the "action plan to further improve medical services", the service process has been continuously optimized, the medical quality has been continuously improved, the service mode has been continuously innovated, and the doctor-patient relationship has been continuously harmonious. 2017 The Health Planning Commission and the State Administration of Traditional Chinese Medicine have identified 11 key tasks to further improve medical services, including expanding the real-name appointment diagnosis and treatment pilot.
In addition, the General Office of the State Council issued a blockbuster document entitled "Several Opinions on Further Reforming and Improving Drug Production, Circulation and Use Policies" on 2 January 9 , which aroused strong repercussions in the pharmaceutical industry. The "opinion" points out that starting from the three major links of drug production, circulation and use is an important reform document covering the entire pharmaceutical industry chain, which will play a key role in further promoting the supply-side structural reform of the pharmaceutical industry. it will also have a far-reaching impact on the future healthy development of the pharmaceutical industry.
If 2016 is the year of supply-side reform, then 2017 will be the year of deepening the supply-side reform of medical reform. Supply-side structural reform has become the key word of this year's "two sessions" medicine.
2 , medical reform: the formation of a basic medical and health system framework
medical reform has always been a hot issue of concern. the key work points of 2017 published by the health planning Commission proposed that the medical reform should be continuously deepened and the formation of a basic medical and health system framework should be accelerated. These include measures such as promoting the hierarchical diagnosis and treatment system, accelerating the establishment of a modern hospital management system, and implementing the reform of the drug supply guarantee system. In addition, medical reform has also been mentioned in the government work reports of the local two sessions that have been implemented, and various localities have "bright moves" to solve the problem of people seeing a doctor ".
Zhejiang Province has achieved "double sinking and two upgrading" of medical resources through the establishment of a medical consortium, alleviating the current situation of people's difficulty in seeing a doctor, and accelerating the reform of "Internet + medical prices.
medical reform has always been one of the key reform projects promoted by the State Council. Deepening the reform of the medical and health system and strengthening the construction of the medical service system will become the focus of attention and heated discussion among the representatives of the two sessions.
3 , medical and nursing integration: make up for shortcomings and solve the pension problem
With the increasing aging of the population, new requirements have been put forward for the development of medical care. In the "Several Opinions on Accelerating the Development of Elderly Care Services" issued by the State Council in 2013 , it was proposed to "promote the integrated development of medical care and elderly care", which pointed out the direction for the development of my country's elderly care industry. This year, Zhejiang proposed to actively promote the reform of the old-age insurance system, study and formulate a linkage adjustment mechanism for the basic pension for retirees and the minimum standard of basic pension for urban and rural residents, and steadily raise the standards of basic pension and basic pension.
At the National Two Sessions, elderly care has become an issue of high concern, and the quality of life of the elderly in their later years will affect the stability of the entire society. How to improve the quality of elderly care services has received special attention.
4
, Pollution Control: Hundreds of pharmaceutical companies may face suspension of production. Environmental protection has always been a topic of close attention throughout the country. According to the data of the legal network voting system, as of 2017
2 April 28 , smog control ranked among the top 10 hot spots of the NPC and CPPCC with 19598 votes. 2017 is the second year of the 13th Five-Year Plan and a key year for environmental protection. Last year in the middle and late of December 1, there was a large-scale continuous severe air pollution in our country. Satellite monitoring shows that the scope of smog was once expanded to 17
provinces, autonomous regions and municipalities in, covering an area of 142 .09 million square kilometers, that is to say, more than 1/7 of the country was shrouded in smog. With such a "power" of the haze, naturally become the focus of attention of the various provinces. It is no longer news to use ten "haze" volts to describe the weather in Beijing-Tianjin-Hebei region during winter heating. However, after the Spring Festival this year, the "Beijing-Tianjin-Hebei and Surrounding Areas Air Pollution Prevention and Control Work Plan for 2017
(Draft for Comments ) " ( hereinafter referred to as "Plan" ) once again pushed pharmaceutical companies in the region to the forefront. If this "plan" becomes a reality, hundreds of pharmaceutical enterprises in "2+26 " cities such as Beijing, Tianjin, Shijiazhuang, Jinan, Zhengzhou and Taiyuan will not be allowed to produce for 120 days throughout the year. According to the implementation promotion plan of ( Ten Atmospheric Articles
)issued by the State Council in 2013 , 2017 is the final assessment year of the action plan. Environmental protection has naturally become one of the hot words of the two sessions this year.
, Reform of State-owned Enterprises: Mixed Reform of Pharmaceutical Enterprises Station in UpportSince 2016
, various regions have successively issued a number of special supporting documents to implement the "Guiding Opinions on Deepening the Reform of State-owned Enterprises" promulgated and implemented by the CPC Central Committee and the State Council, and the "four beams and eight pillars" of the reform of state-owned enterprises have risen, accelerate from "design" to "construction".1 Since September, the local two sessions have been intensively held, and the reform of state-owned enterprises has once again become the focus of the local "two sessions. 2016
# Decemberth June 29 , Yunnan Baiyao controlling shareholder Baiyao Holdings introduced about 254 billion yuan to Xinhuadu Industrial Group Co., Ltd. through capital increase. Baiyao Holding's equity structure was changed to Yunnan SASAC and Xinhuadu each holding 50% equity. At present, the company's core business consists of the provincial pharmaceutical company, the pharmaceutical division, the health products division and the traditional Chinese medicine resources division, which are respectively responsible for the four major business sectors of pharmaceuticals, health daily chemical products, traditional Chinese medicine resources products and pharmaceutical commerce. The initial completion of the mixed reform plan of Baiyao Holdings has made Yunnan Baiyao a model of performance growth in the pharmaceutical industry. Since the listing of in 1993 , Yunnan Baiyao has led its peers in performance growth. Compared with listed companies under state-owned enterprises in Yunnan Province, Yunnan Baiyao's return on net assets and other indicators are also far ahead. In the report on accelerating the reform of state-owned enterprises recently released by the Tianjin State-owned Assets Supervision and Administration Commission, the timetable and roadmap for Tianjin Pharmaceutical Group Co., Ltd. to promote the reform of state-owned enterprises clearly emerged. Among them, increasing the intensity of mixed reform, using the listing platform to achieve asset securitization and improving the assessment and incentive mechanism have become the three highlights. Some pharmaceutical industry analysts pointed out that from the perspective of the reform route, Tianyao Group has continued the overall thinking of the current state-owned enterprise reform. It is another typical case of initiating the reform of state-owned enterprises in the pharmaceutical industry after Yunnan Baiyao.
pharmaceutical enterprise reform results show, the company's profitability and overall value has been further improved. On the basis that the top-level design of the reform of state-owned enterprises has been basically completed, the reform of pharmaceutical state-owned enterprises will gradually reach a climax in 2017
, which will affect the future direction of pharmaceutical investment to a certain extent. (article from the network)
More information
Two Cement Enterprises Prosperous Production and Sales in May
With the gradual easing of the new crown epidemic, all over the project has started, Hubei, Yunnan two provinces cement market continued to improve, Daye peak cement company, Yunnan peak cement company two enterprises have recently shown a good momentum of production and sales. In May, the sales volume of Yunnan Jianfeng cement continued to rise. As of the time of publication, the average daily shipment volume reached more than 7400 tons, and the highest daily shipment volume reached more than 8700 tons, and the production capacity was fully released. Over the past few days, Yunnan Peak Packaging System has made great efforts to overcome the impact of narrow distribution sites and many cement varieties to ensure the completion of delivery tasks with good quality and quantity every day. In order to further balance production and sales and create conditions for the homogenization of cement delivered from the factory, Yunnan peak packaging system puts forward work requirements for relevant posts, emphasizes equipment inspection and process inspection during production, strictly implements safety operation procedures, and maintains safe and efficient operation of the system. Due to the impact of the new crown epidemic, Hubei cement market started late, Wuhan market is the hardest hit area, the current project construction is still not fully started, the volume pressure is greater. For this reason, daye peak departments cooperate closely, increase market development efforts, develop new mixing stations, focus on increasing the bulk share of Xianning, Huanggang and Wuhan markets, seize the opportunity of fine weather, and achieve the goal of rapid output. Internally, on the basis of equipment technical renovation and production capacity improvement, the delivery is effectively guaranteed, and the daily delivery capacity can basically be maintained at 10,000 tons. In May, Daye Peak sold more than 300000 tons of cement, an increase of 20% over the same period last year, with an average daily sales volume of more than 9900 tons, the highest in the current period since Daye Peak was put into production.
2020
07-31
The company's "safe production month" activities are about to start
June 2020 is the 19th national "safe production month", the theme of the activity is "eliminating hidden dangers of accidents and building a strong line of defense". A few days ago, the group company issued a notice to arrange the activities related to the organization of "safe production month" and put forward requirements. According to the group's "safe production month" activity plan, different key thematic activities will be held in the four weeks of June. The first week is the "Publicity and Safety Education Week", which focuses on the use of WeChat groups, electronic screens, publicity boards, banners, slogans and other forms for safety publicity, and organizes the study of national safety regulations, company safety system specifications and accident-free factory creation standards, Organize to watch safety warning education films, learn accident cases, etc., and improve employees' safety awareness by creating a safety atmosphere and organizing learning activities. The focus of the activities in the second week is "looking for potential sources of danger around you". Each unit takes departments and teams as units to investigate and analyze the potential risk factors in the process of daily production, maintenance and operation, find out the hazard sources that have not been included in the scope of risk point control, and report to the safety management department of the unit to form a risk assessment report, put forward solutions or suggestions, and supervise the implementation of rectification and timely eliminate potential safety hazards. The third week is the "on-site safety innovation achievements exhibition week", which focuses on the achievements of each unit in on-site safety management and on-site safety facilities in the past year, which are displayed in the form of pictures and texts through beautiful articles and wechat, so as to learn from each other and promote common progress. The fourth week is the "safety training and drill week", and the group company organizes the standardization of safety production and the elimination of hidden dangers.
2020
07-31
Jianfeng Pharmaceuticals ranks among the top 50 creative enterprises in Jinhua
News from our newspaper April 26 is World Intellectual Property Day. Jinhua City released the list of "Top 50 Creative Enterprises" for the first time. Jianfeng Pharmaceutical Company entered the list and ranked second among the enterprises in Jinhua Development Zone. The selection of creative enterprises, the enterprise holds the effective invention patent as the main indicator. Over the years, Jianfeng Pharmaceutical Co., Ltd. has taken "intellectual property rights help enterprise development, and scientific and technological innovation creates a century-old peak" as the company's intellectual property policy. It has actively cooperated with China Pharmaceutical University, Sichuan Institute of Antibiotic Industry, Zhejiang University of Technology, Xiamen University and other units to build a scientific research and innovation platform integrating production, learning and research, and flexibly introduced Academician Wang Guangji and Academician Shan Weiguang with the chief scientist system, according to the direction of enterprise development strategy to carry out scientific research work, and achieved fruitful results. In 2019, Spike Pharmaceuticals applied for 2 invention patents and obtained 5 patent authorizations, including 1 invention. By the end of 2019, Spike Pharmaceuticals had obtained a total of 37 patents (including 2 PCT patents), of which 28 were inventions. In recent years, in order to better integrate with the international market, Jianfeng Pharmaceutical has made a complete patent layout for the new drug DPT under development, and has applied for patent protection in multiple countries through the PCT application channel for core patents, and finally in the high-level United States. And Japan was authorized to lay a solid foundation for the product to enter these two overseas high-end markets. At the same time, around the core patent, applied for the preparation, crystal type patent and obtained the invention patent authorization 5. In addition, pharmaceutical companies have also developed patents for other varieties under research.
2020
07-31
Jianfeng Pharmaceuticals ranks among the top 50 creative enterprises in Jinhua
News from our newspaper April 26 is World Intellectual Property Day. Jinhua City released the list of "Top 50 Creative Enterprises" for the first time. Jianfeng Pharmaceutical Company entered the list and ranked second among the enterprises in Jinhua Development Zone. The selection of creative enterprises, the enterprise holds the effective invention patent as the main indicator. Over the years, Jianfeng Pharmaceutical Co., Ltd. has taken "intellectual property rights help enterprise development, and scientific and technological innovation creates a century-old peak" as the company's intellectual property policy. It has actively cooperated with China Pharmaceutical University, Sichuan Institute of Antibiotic Industry, Zhejiang University of Technology, Xiamen University and other units to build a scientific research and innovation platform integrating production, learning and research, and flexibly introduced Academician Wang Guangji and Academician Shan Weiguang with the chief scientist system, according to the direction of enterprise development strategy to carry out scientific research work, and achieved fruitful results. In 2019, Spike Pharmaceuticals applied for 2 invention patents and obtained 5 patent authorizations, including 1 invention. By the end of 2019, Spike Pharmaceuticals had obtained a total of 37 patents (including 2 PCT patents), of which 28 were inventions. In recent years, in order to better integrate with the international market, Jianfeng Pharmaceutical has made a complete patent layout for the new drug DPT under development, and has applied for patent protection in multiple countries through the PCT application channel for core patents, and finally in the high-level United States. And Japan was authorized to lay a solid foundation for the product to enter these two overseas high-end markets. At the same time, around the core patent, applied for the preparation, crystal type patent and obtained the invention patent authorization 5. In addition, pharmaceutical companies have also developed patents for other varieties under research.
2020
07-30
Jianfeng Pharmaceuticals ranks among the top 50 creative enterprises in Jinhua
News from our newspaper April 26 is World Intellectual Property Day. Jinhua City released the list of "Top 50 Creative Enterprises" for the first time. Jianfeng Pharmaceutical Company entered the list and ranked second among the enterprises in Jinhua Development Zone. The selection of creative enterprises, the enterprise holds the effective invention patent as the main indicator. Over the years, Jianfeng Pharmaceutical Co., Ltd. has taken "intellectual property rights help enterprise development, and scientific and technological innovation creates a century-old peak" as the company's intellectual property policy. It has actively cooperated with China Pharmaceutical University, Sichuan Institute of Antibiotic Industry, Zhejiang University of Technology, Xiamen University and other units to build a scientific research and innovation platform integrating production, learning and research, and flexibly introduced Academician Wang Guangji and Academician Shan Weiguang with the chief scientist system, according to the direction of enterprise development strategy to carry out scientific research work, and achieved fruitful results. In 2019, Spike Pharmaceuticals applied for 2 invention patents and obtained 5 patent authorizations, including 1 invention. By the end of 2019, Spike Pharmaceuticals had obtained a total of 37 patents (including 2 PCT patents), of which 28 were inventions. In recent years, in order to better integrate with the international market, Jianfeng Pharmaceutical has made a complete patent layout for the new drug DPT under development, and has applied for patent protection in multiple countries through the PCT application channel for core patents, and finally in the high-level United States. And Japan was authorized to lay a solid foundation for the product to enter these two overseas high-end markets. At the same time, around the core patent, applied for the preparation, crystal type patent and obtained the invention patent authorization 5. In addition, pharmaceutical companies have also developed patents for other varieties under research.
2020
07-22
On April 24, Jiang Xiaomeng, chairman of the group company, presided over the 14th meeting of the 10th board of directors of the company, and deliberated and passed 14 related reports and motions such as the 2019 annual board of directors report, the 2019 general manager business report and the 2019 annual report. The general manager's report pointed out that 2019 is the first year of the implementation of the group's new five-year strategic development plan (2019-2023) and the new three-year business plan (2019-2021) for each business sector. the management team has carried out various operation and management work in an orderly manner around the general policy of "innovation and reform, integration and promotion, scientific layout and steady development", and has better completed the business objectives set by the board of directors at the beginning of the year. In the whole year, the company achieved a total operating income of 3.548 billion billion yuan, an increase of 5.51 percent over the same period last year; net profit attributable to shareholders was 0.725 billion billion yuan, with earnings per share reaching 2.11 billion yuan, an increase of 23.14 percent over the same period last year, a record high; total assets at the end of the year were 5.475 billion billion yuan, an increase of 11.71 percent over the same period last year; and net assets attributable to shareholders were 3.789 billion billion yuan, an increase of 19.81 percent. During the reporting period, the company's two main businesses have achieved great development, benefiting from the further promotion of supply-side structural reform, the overall operation of the cement industry in 2019 is stable, and the industry benefits are further improved. During the reporting period, the company made new progress in the construction of cement projects, completed the acquisition, capital increase and name change of Guizhou Mingchuan (Guizhou Huangping Jianfeng Cement Co., Ltd.), and continued to invest in the construction of its new dry cement production line with a daily output of 4500 tons of clinker.
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page